Hananja

EPILEPTIC SEIZURES: NEW EFFECTIVE TREATMENT IN SIGHT

E-mail Print PDF

Intranasal delivery
Epilepsy is caused by disturbed electrical activity in the brain and has been recognized for at
least 2400 years. It is expressed as a collection of many different types of seizures that vary
widely in severity, appearance, cause, consequence and management. Its most severe form,
status epilepticus, is a neurological emergency that may result in brain damage or death.
Seizures should be treated as soon as possible. From onset of seizures and until the initiation
of the treatment should be as short as possible, to reduce the damage seizures can cause as
well as the risk of morbidity and mortality.

 

 

 

 

Today there are two administration routes used:
1. Intravenous (IV) delivery of e.g. benzodiazepines. A method used for institutionalized
patients, where trained personnel is equipped to treat these conditions. Family, friends and
coworkers cannot and do not use this method, but call for an ambulance.
2. Rectal delivery of clysma is a method used to treat seizures in children, but not in
adolescents or adults. Within family or in hospitalized patients, rectal delivery is possible.
However, when outside e.g. in an airplane, at work or in a shopping mall, this method is
not used.

New method has entered phase III clinical trials:
Hananja ehf and the University of Iceland has developed an intranasal formulation for the
treatment of epileptic seizures. Nasal administration is easy for all family members, coworkers
and friends when an epileptic patient need such treatment. Under an agreement with Ikano
Therapeutics Inc. [Press-Release-2007] the product was carried through Preclinicals, Phase I
and Phase II clinical trials. In January 2010 US-FDA approved Phase III clinical trial. From
August 2010 Upsher-Smith Laboratories [PressRelease-UpsherSmith] will continue the work
and bring the product through Phase III clinical trials and to the world-wide market.

 
Þú ert hér: Home News EPILEPTIC SEIZURES: NEW EFFECTIVE TREATMENT IN SIGHT

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com